Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 55

1.

Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.

Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB.

Clin Neuropharmacol. 2010 Mar-Apr;33(2):67-73. doi: 10.1097/WNF.0b013e3181cb577a.

PMID:
20375655
[PubMed - indexed for MEDLINE]
2.

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M.

Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26.

PMID:
20189881
[PubMed - indexed for MEDLINE]
3.

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.

Blennow K, Hampel H, Weiner M, Zetterberg H.

Nat Rev Neurol. 2010 Mar;6(3):131-44. doi: 10.1038/nrneurol.2010.4. Epub 2010 Feb 16. Review.

PMID:
20157306
[PubMed - indexed for MEDLINE]
4.

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ.

Lancet Neurol. 2010 Jan;9(1):119-28. doi: 10.1016/S1474-4422(09)70299-6.

PMID:
20083042
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

mAbs: a business perspective.

Scolnik PA.

MAbs. 2009 Mar-Apr;1(2):179-84. Epub 2009 Mar 21. Review.

PMID:
20061824
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M; Bapineuzumab 201 Clinical Trial Investigators.

Neurology. 2009 Dec 15;73(24):2061-70. doi: 10.1212/WNL.0b013e3181c67808. Epub 2009 Nov 18.

PMID:
19923550
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Applications of neuroimaging to disease-modification trials in Alzheimer's disease.

Fleisher AS, Donohue M, Chen K, Brewer JB, Aisen PS; Alzheimer's Disease Neuroimaging Initiative.

Behav Neurol. 2009;21(1):129-36. doi: 10.3233/BEN-2009-0241. Review.

PMID:
19847051
[PubMed - indexed for MEDLINE]
8.

Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo.

Rabinovici GD, Jagust WJ.

Behav Neurol. 2009;21(1):117-28. doi: 10.3233/BEN-2009-0232. Review.

PMID:
19847050
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta.

Yamada K, Yabuki C, Seubert P, Schenk D, Hori Y, Ohtsuki S, Terasaki T, Hashimoto T, Iwatsubo T.

J Neurosci. 2009 Sep 9;29(36):11393-8. doi: 10.1523/JNEUROSCI.2021-09.2009.

PMID:
19741145
[PubMed - indexed for MEDLINE]
Free Article
10.

The role of apolipoprotein E in Alzheimer's disease.

Kim J, Basak JM, Holtzman DM.

Neuron. 2009 Aug 13;63(3):287-303. doi: 10.1016/j.neuron.2009.06.026. Review.

PMID:
19679070
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Cholinesterase inhibition: is there evidence for disease-modifying effects?

Shanks M, Kivipelto M, Bullock R, Lane R.

Curr Med Res Opin. 2009 Oct;25(10):2439-46. doi: 10.1185/03007990903209332. Review.

PMID:
19678754
[PubMed - indexed for MEDLINE]
12.

Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.

Lemere CA.

Prog Brain Res. 2009;175:83-93. doi: 10.1016/S0079-6123(09)17506-4. Review.

PMID:
19660650
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Update on the use of memantine in Alzheimer's disease.

van Marum RJ.

Neuropsychiatr Dis Treat. 2009;5:237-47. Epub 2009 May 20.

PMID:
19557118
[PubMed]
Free PMC Article
14.

Bridging physiology and pathology in AD.

Kim D, Tsai LH.

Cell. 2009 Jun 12;137(6):997-1000. doi: 10.1016/j.cell.2009.05.042. Review.

PMID:
19524503
[PubMed - indexed for MEDLINE]
Free Article
15.

The amyloid hypothesis for Alzheimer's disease: a critical reappraisal.

Hardy J.

J Neurochem. 2009 Aug;110(4):1129-34. doi: 10.1111/j.1471-4159.2009.06181.x. Epub 2009 May 18. Review.

PMID:
19457065
[PubMed - indexed for MEDLINE]
16.

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders.

Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M; AN1792 (QS-21)-251 Study Team.

Curr Alzheimer Res. 2009 Apr;6(2):144-51.

PMID:
19355849
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'?

Jicha GA.

Expert Opin Biol Ther. 2009 Apr;9(4):481-91. doi: 10.1517/14712590902828285 . Review.

PMID:
19344284
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Development of AFFITOPE vaccines for Alzheimer's disease (AD)--from concept to clinical testing.

Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F, Schmidt W.

J Nutr Health Aging. 2009 Mar;13(3):264-7. Review.

PMID:
19262965
[PubMed - indexed for MEDLINE]
19.

Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease.

Muñoz-Torrero D.

Curr Med Chem. 2008;15(24):2433-55. Review.

PMID:
18855672
[PubMed - indexed for MEDLINE]
20.

Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease.

Bacher M, Depboylu C, Du Y, Noelker C, Oertel WH, Behr T, Henriksen G, Behe M, Dodel R.

Neurosci Lett. 2009 Jan 16;449(3):240-5. doi: 10.1016/j.neulet.2008.08.083. Epub 2008 Sep 3.

PMID:
18786612
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk